Mark Fisher, MD
Rheumatology · Boston, MANPI 1932308244
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by AbbVie at 55.0% of the total. 2025 is the largest year on record at $274, more than ten times the $19 reported in 2021. That places this record below the midpoint for rheumatology clinicians in MA, where the typical reported total is $408.
Across 22 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$187
- Organon$57
- Tonix Medicines, Inc.$31
- Amgen$24
- Novartis$23
- Lilly USA, LLC$19
Across 29 payments — averaging $3180.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$92K
What the payments were for
- Food & beverage$341100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 13 | $187 |
| Organon | 4 | $57 |
| Tonix Medicines, Inc. | 2 | $31 |
| Amgen | 1 | $24 |
| Novartis | 1 | $23 |
| Lilly USA, LLC | 1 | $19 |
How this compares
$341 in reported general payments places this provider in the 45th percentile of 265 rheumatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 60 | $429,283 |
| Humira(Cf) PenAdalimumab | 47 | $354,322 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 38 | $290,456 |
| Xeljanz XrTofacitinib Citrate | 47 | $264,890 |
| Orencia ClickjectAbatacept | 28 | $192,305 |
| StelaraUstekinumab | 12 | $191,096 |
| Cimzia (2 Pack)Certolizumab Pegol | 26 | $172,517 |
| Taltz AutoinjectorIxekizumab | 24 | $167,660 |
| Cosentyx Unoready PenSecukinumab | 17 | $145,309 |
| Actemra ActpenTocilizumab | 26 | $113,695 |
| SimponiGolimumab | 16 | $97,395 |
| RinvoqUpadacitinib | 14 | $91,092 |
| KevzaraSarilumab | 21 | $89,324 |
| InflectraInfliximab-Dyyb | 17 | $88,055 |
| Cosentyx Sensoready PenSecukinumab | 11 | $80,458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Savella | $187 | $104,22630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 265 rheumatology providers in Massachusetts.
Other rheumatology in Boston
- Marilyn PikeBoston$1.4M
- John StoneBoston$926K
- Lee SimonBoston$600K
- Jeffrey SparksBoston$299K
- Tanya LaidlawBoston$244K
- Tuhina NeogiBoston$242K
- Michael WeinblattBoston$228K
- Michael BrennerBoston$115K
- Zachary WallaceBoston$106K
- Flavia CastelinoBoston$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.